Cutia Therapeutics (HK:2487) has released an update. Cutia Therapeutics’ CEO, Ms. Zhang Lele, has further increased her stake in the ...

Cutia Therapeutics (HK:2487) has released an update. Cutia Therapeutics has announced the completion of a Phase II clinical trial for CU-20401, ...

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally administered, brain penetrant inhibitor of PRMT5 MORRISVILLE, N.C., Oct. 25, ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

RESEARCH TRIANGLE PARK, N.C, Oct. 22, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating ...

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development. New investor Bedford Ridge Capital and existing ...

LOS ANGELES--(BUSINESS WIRE)--Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using ...

The reverse stock split was approved by Kintara's stockholders at Kintara's special meeting of stockholders held on October 4, 2024, to be effected in the Board's discretion of not less than 1-for ...

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ...